Asset Details
Do you wish to reserve the book?
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Do you wish to request the book?
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
2025
Overview
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
Subject
/ Antibodies - therapeutic use
/ Antibodies, Bispecific - therapeutic use
/ Antigens
/ B cells
/ Blood coagulation factor VIII
/ Disease
/ Hematologic Diseases - drug therapy
/ Hematologic Neoplasms - drug therapy
/ Humans
/ Lymphoma
/ Myeloma
/ Paroxysmal nocturnal hemoglobinuria
/ Review
/ T cells
/ Toxicity
